INTRODUCTION
============

Ubiquitin (Ub) is a highly conserved 76-amino acid (8.5 kDa) protein present in all eukaryotic cells. Ub is covalently conjugated to other proteins in a reversible manner, in order to alter its substrate's fate and biological function at multiple levels in a process called "ubiquitination" ([@b30-molce-41-3-168]). Ub can be attached to substrate proteins as a single molecule or in polymeric chains that are connected through specific isopeptide bonds to form a branched or forked structure ([@b41-molce-41-3-168]). Ubiquitination is a dynamic, highly regulated process that involves successive steps of Ub activation, conjugation and ligation. First, Ub-activating enzymes (E1s) activate Ub in an ATP-dependent reaction (an energy-consuming step) to generate a thioester-linked E1\~Ub conjugate. Second, the activated Ub is transferred via a transthiolation reaction to the cysteine residue of an Ub-conjugating enzyme (E2) ([@b93-molce-41-3-168]). Finally, the C-terminal glycine of Ub is conjugated to a specific lysine on the target protein by Ub ligases (E3s) ([@b57-molce-41-3-168]). The Ub tags or chains can be removed from target proteins by a family of isopeptidases called deubiquitinases (DUBs), which reverse the function of ubiquitination ([@b42-molce-41-3-168]).

As one of the most important cellular post-transcriptional mechanisms, ubiquitination is involved in a wide range of key physiological processes ([@b24-molce-41-3-168]). Although it plays its best-known and best-characterized role in the mediation of targeted protein degradation via the 26S proteasome, many lines of evidence have shown that ubiquitination also acts as a crucial regulator of transcription, DNA repair, endocytosis, plasma membrane receptor recycling, intracellular trafficking, inflammatory signaling and angiogenesis ([@b61-molce-41-3-168]). This functional diversity is driven in part by the specific positions in the ubiquitin molecule of the lysine (K) residues (e.g., K6, K11, K27, K29, K33, K48, or K63) that are involved in monomer or polymeric chain formation ([@b41-molce-41-3-168]). It has been repeatedly shown that deregulation of the ubiquitination process contributes to the pathogenesis of a wide range of diseases, including cancer, neurodegenerative disorders, immune disease, diabetes, muscle atrophy and other debilitating conditions.

While the action modes of E3s in various diseases are already the focus of much current research, limited attention has been paid to the pathogenetic role of E2s. In this review, we will explore recent advances in our understanding of the roles of E2 enzymes (in particular ubiquitin-conjugating enzyme E2O \[UBE2O\]) in the pathogenesis and progression of human diseases, and discuss the possibility that E2s could serve as potential targetsin therapeutic interventions.

E2 STRUCTURE AND SUPERFAMILY
============================

To date, approximately 40 E2s have been identified, while 2 E1s and approximately 600\~1000 E3s are known to be encoded in the human genome. A defining characteristic of all E2s (14\~35 kDa at average mass) is a conserved catalytic "core" domain of 150--200 amino acids (the Ub-conjugating domain, or UBC); these domains of 14--16 kDa are \~35% conserved among different family members ([@b16-molce-41-3-168]). The E2 UBC domain typically adopts an α/β-fold with four α-helices and a four-stranded β-sheet ([Fig. 1](#f1-molce-41-3-168){ref-type="fig"}). Important loop regions constitute a portion of the E3-binding site (L1 loop and L2 loop) and the active site (L3 loop). Within the UBC, the catalytic cysteine residue required for Ub thioester formation is adjacent to an invariant asparagine residue, and together these compose the well-established Ub binding cleft; thus suppression of Ub conjugation and deconjugation for pharmacological intervention could prove a promising approach for disease therapy (as further discussed below).

E2s are classified into 4 different types: class I contains only the UBC domain, classes II and III have either N- or C--terminal extensions, respectively, and class IV E2s have both N- and C-terminal extensions ([Fig. 2](#f2-molce-41-3-168){ref-type="fig"}). These extra domains not only create E2s of diverse molecular size, including the largest E2s, UBE2O (1,292 amino acids) and BIRC6 (4,857 amino acids), but can also govern intracellular localization, confer regulatory properties, and enable specific interactions with particular E3s ([@b93-molce-41-3-168]; [@b88-molce-41-3-168]).

E2 REACTIVITY
=============

In general, E2s are engaged in Ub transfer reactions: (1) transthiolation (transfer from a thioester to a thiol group) and (2) aminolysis (transfer from a thioester to an amino group). The C-terminal carboxylate of Ub is conjugated to the E2 active site cysteine in an E1-catalyzed, ATP-driven reaction. E3s recruit E2s\~Ub complexes (\~ denotes a thioester linkage) and a substrate to promote Ub transfer, most commonly onto the ɛ-amino group of a lysine in the target protein, forming an isopeptide bond. Three classes of E3s have been identified to date - RING (really interesting new gene), HECT (homologous to E6AP C-terminus) and RBR (RING-between-RING) ([@b7-molce-41-3-168]). The RING E3s prime E2s\~Ub for transfer by promoting a closed E2s\~Ub conformation in which the thioester is activated toward nucleophilic attack on the substrate lysine ([@b59-molce-41-3-168]). Alternatively, Ub is transferred from E2s to the catalytic cysteine on the C-lobe of the HECT domain in a transthiolation reaction, and HECT\~Ub is subsequently juxtaposed with a substrate lysine to which Ub is transferred ([@b36-molce-41-3-168]). Analyses of the crystal structures of RBR E3 have revealed that RING1 recruits E2\~Ub and transfers Ub to the catalytic cysteine on RING2 to form a RING2\~Ub intermediate; Ub is subsequently transferred to the lysine substrate on the target protein ([@b45-molce-41-3-168]). E2--E3 interactions are also important because the interacting E2s dictate the specific type of inter-Ub linkage (i.e., K48 or K63) and thereby determine the ultimate fate of a substrate (i.e., targeted by the 26S proteasome for degradation or involved in signaling) ([@b78-molce-41-3-168]).

E2 ACTION INDEPENDENT OF E3
===========================

E2s can interact with and ubiquitinate substrates without the participation of E3s both *in vitro* and in intact cells. For example, UBCH5 and UBCH7 monoubiquitinate STS2 (or UBS3A) to promote its ability to regulate cargo (i.e., EGFR) sorting ([@b32-molce-41-3-168]); in this case, E2s can bind to the ubiquitin-binding domain (UBD) of the target substrate via the Ub attached to its catalytic cysteine, prior to the Ub being passed to the lysine residue of the substrate. Another E3-independent mechanism, SETDB1, differs from coupled monoubiquitination in that it does not require a functional UBD. Instead, SETDB1 ubiquitination is directly catalyzed by UBE2E, which surprisingly acts as a functional E3 or UBD ([@b79-molce-41-3-168]). UBE2A/B--EEA1 interactions likewise enable E3-independent mechanisms that decorate EEA1 with a mono-Ub moiety for endosome fusion and trafficking ([@b65-molce-41-3-168]).

Intriguingly, a few E2s (e.g., BIRC6 and UBE2O) could be described as parts of large multi-domain proteins, and act as E2/E3 hybrids. These atypical E2 members perform the second and third steps in the ubiquitination reaction, combining the activities of regular E2s and E3s. Once loaded with Ub from E1\~Ub complex, these E2s can bind a substrate and transfer Ub to a lysine residue of that substrate protein. For example, BIRC6 (also known as BRUCE or Apollon) does not require any additional enzymes beyond E1 for ubiquitination of its substrate, Smac/DIABLO, in cell death pathways ([@b4-molce-41-3-168]). In this enzyme, the N-terminal BIR domain may mediate substrate binding in a manner analogous to E3s, whereas the UBC domain at the C-terminal end of the BIRC6 protein enables catalytic Ub-conjugation activity.

PATHOLOGICAL ROLES OF E2 IN HUMAN DISEASES
==========================================

E2s have emerged as important pathogenetic factors for human diseases including neurodegenerative disorders, chromosome instability syndromes, immunological disorders and cancer ([Table 1](#t1-molce-41-3-168){ref-type="table"}).

Neurodegenerative disorders
---------------------------

E2s are implicated in the pathogenesis of several neurological diseases. Mutations in genes encoding the Parkin E3 ligase are the most frequent causes of early-onset familial Parkinson disease ([@b37-molce-41-3-168]). Parkin performs an essential neuroprotective function by regulating mitophagy, which is key to the maintenance of mitochondrial homeostasis ([@b34-molce-41-3-168]). Recent works have revealed that UBE2D2/3, UBE2L3, UBE2N and UBE2R1 regulate the activity and cellular compartmentalization of Parkin, and thereby impact the Parkin-mediated clearance of damaged mitochondria ([@b19-molce-41-3-168]; [@b23-molce-41-3-168]). *UBE2A* has been identified as an intellectual disability gene and shown to act with Parkin to promote ubiquitination of mitochondrial proteins and mitophagy ([@b26-molce-41-3-168]). UBE2K interacts with and ubiquitinates huntingtin, the gene product of Huntington disease, and promotes aggregate formation of expanded polyglutamine proteins and apoptosis in polyglutamine diseases ([@b14-molce-41-3-168]). These results suggest that E2s play an important role in the pathology of neurological diseases.

Chromosome instability syndromes
--------------------------------

Fanconi anemia (FA) is a rare genetic disorder affecting bone marrow function and hematopoiesis ([@b48-molce-41-3-168]). The FA DNA repair pathway has become a paradigm for the physiological importance of Ub signaling in coordination of DNA repair pathways and the maintenance of genome stability ([@b10-molce-41-3-168]). UBE2T was identified as the cognate E2 for monoubiquitination of the FA proteins FANCD2/FANCL, a key step in the signal transduction cascade of the FA DNA repair pathway ([@b51-molce-41-3-168]). Furthermore, genomic analysis of FA patients has revealed that allelic alterations of *UBE2T* are associated with loss of function and deficiency of UBE2T protein ([@b31-molce-41-3-168]). Overall, *UBE2T* is now recognized as a bona fide FA gene (and has been alternatively named *FANCT*).

Immunological disorders
-----------------------

Several genome-wide association studies have identified polymorphisms in the genomic locus of *UBE2L3* as high risk factors for developing systemic lupus erythematosus and rheumatoid arthritis ([@b27-molce-41-3-168]; [@b77-molce-41-3-168]). Notably, UBE2L3 can form specific E2--E3 pairs with the disease-associated E3 ligase LUBAC (linear ubiquitin chain assembly complex), a critical factor in the efficient activation of NF-κB signaling ([@b33-molce-41-3-168]). This evidence suggests UBE2L3 may play a role in regulating inflammation and immunity signaling pathways in autoimmune diseases.

Cancer
------

Multiple studies have found deregulated expression of E2s in various cancers, and growing evidence indicates that during malignant transformation, many E2s promote DNA repair, cell cycle progression, and activation of oncogenic signaling pathways, while inhibiting apoptosis ([Table 1](#t1-molce-41-3-168){ref-type="table"}). Thus, E2s may be key to identifying potential cancer susceptibility genes for diagnosis and prognosis, and could play a role in the design of novel therapies.

UBE2O AS A KICK-STARTER FOR DISEASES AND CANCER
===============================================

Mechanisms of action of UBE2O
-----------------------------

The large UBE2O, though a single entity, essentially operates as a combination of E2 and E3 enzymes ([@b38-molce-41-3-168]; [@b5-molce-41-3-168]); it is also capable of interacting cooperatively with the E3 RING ligase MAGE-L2/TRIM27, suggesting it can play multi-functional roles ([@b28-molce-41-3-168]). It has been proposed that ubiquitination by UBE2O involves an intramolecular thioester relay mechanism, as this enzyme is inhibited by arsenites which can crosslink adjacent cysteines ([@b38-molce-41-3-168]). UBE2O possesses three conserved regions (CR1, CR2 and CR3) and a coiled-coil (CC) domain ([Fig. 3](#f3-molce-41-3-168){ref-type="fig"}). The CR1 and CR2 domains are both believed to recognize the same targeted substrates, although their binding specificity varies ([@b52-molce-41-3-168]; [@b56-molce-41-3-168]). Interestingly, [@b52-molce-41-3-168] have established a putative targeting consensus sequence for UBE2O (i.e., K/R and VLI patches: \[KR\]\[KR\]\[KR\]-X(1,3)-\[VLI\]-X-\[VLI\]-X-X-\[VLI\]) and have identified potential targets, several of which have tested positive experimentally for UBE2O-mediated ubiquitination. Like other E2s, UBE2O has a conserved core UBC domain in the C-terminus that can interact with multiple E3s. However, ubiquitination of most of the reported UBE2O substrates are catalyzed by UBE2O without E3s. While UBE2O mediates (multi-)monoubiquitination of SMAD6, WASH, BAP1 and α-globin ([@b56-molce-41-3-168]; [@b92-molce-41-3-168]), UBE2O is able to polyubiquitinate AMPKα2 and MLL, leading to their proteasomal degradation ([@b46-molce-41-3-168]; [@b83-molce-41-3-168]). UBE2O is ubiquitously expressed in mammalian tissues, but preferentially in brain, heart, skeletal muscle and liver tissue ([@b94-molce-41-3-168]). Although its cellular localization is predominantly cytoplasmic, UBE2O harbors two putative nuclear localization sequences (NLS) ([@b52-molce-41-3-168]). In addition, UBE2O contains potential sites for phosphorylation and its activity may be regulated by phosphorylation ([@b46-molce-41-3-168]). Thus the specialized features and multifunctional domains within the UBE2O protein suggest that its role in disease pathogenesis includes a broad spectrum of molecular targets and functions.

A role for UBE2O in erythropoiesis and proteostasis
---------------------------------------------------

UBE2O is known to be strongly upregulated in terminally differentiating reticulocytes ([@b87-molce-41-3-168]), and an intriguing study recently demonstrated the crucial role it plays in erythroid differentiation ([@b56-molce-41-3-168])([Fig. 4](#f4-molce-41-3-168){ref-type="fig"}). Mice expressing a truncated mutation in the *Ube2o* gene (known as *hem9*) exhibit hypochromic, microcytic anemia and their reticulocytes show a dramatic reduction in Ub-conjugated protein pools. Significantly, ribosomal proteins are the major targets of UBE2O once it has been reintroduced into *hem9* reticulocyte lysates. In a related finding, *hem9* reticulocytes exhibited elevated levels of ribosomal proteins such as RPL29 and RPL35, a phenotype apparently due to a defect in the elimination of ribosomes. UBE2O can similarly act as a self-contained quality control factor for the recognition and elimination of orphan subunits ([@b92-molce-41-3-168]), and can directly recognize juxtaposed basic and hydrophobic patches on unassembled proteins (e.g., α-globin that fails to assemble with β-globin in reticulocytes) as part of its role in mediating ubiquitination for the maintenance of protein homeostasis. In summary, UBE2O ubiquitinates free ribosomal proteins and unassembled proteins and targets them for degradation to the proteasome, thus playing an important role during terminal erythroid differentiation.

An oncogenic role for UBE2O in cancer: Spinning on the AMPK axis
----------------------------------------------------------------

A careful review of a large-scale genome analysis and associated expression profile data from a panel of human cancers has revealed that many cancers exhibit alterations in *UBE2O*, with amplifications occurring ata particularly high frequency (i.e., in \~20% of human breast, bladder, liver and lung cancers)([@b83-molce-41-3-168]). Notably, *UBE2O* is located in the 17q25 locus, the amplification of which is recurrent in human cancers. Several recent studies have demonstrated that UBE2O acts as an oncogene in various types of cancer. Significantly, [@b83-molce-41-3-168] generated the first *Ube2o* knockout mouse specifically to investigate the oncogenic role of the protein, and in mouse models of prostate and breast cancer (TRAMP \[transgenic adenocarcinoma mouse prostate\] and MMTV-PyVT \[MMTV-polyomavirus middle T antigen\] transgenic mice, respectively), targeted deletion of *Ube2o* has dramatically delayed the onset of prostate and breast tumors and impaired invasion and distant metastasis.

Mechanistically, UBE2O directly interacts with and ubiquitinates AMPKα2 (AMP-activated protein kinase α2) to promote its proteasomal degradation, but leaves AMPKα1 untouched ([Fig. 4](#f4-molce-41-3-168){ref-type="fig"}). Accordingly, in two independent mouse models of lymphoma (Eμ-Myc mouse model of B cell lymphoma and *Pten* loss-driven T cell lymphoma) where AMPKα2 was not detectable, ablation of *Ube2o* did not show significant anti-tumor effects or confer a survival advantage. Moreover, UBE2O promoted activation of the mTOR (mammalian target of rapamycin complex 1)-HIF1α (hypoxia-inducible factor 1α) pathway and reprogrammed cancer cells toward aerobic glycolysis (or the Warburg effect) ([@b82-molce-41-3-168]) and biosynthetic pathways in an AMPKα2-dependent manner. Finally, immunohistochemical and prognostic analyses of cancer patients have highlighted the clinical relevance of UBE2O regulation of the AMPKα2-mTOR-HIF1α axis.

Other pathological roles for UBE2O
----------------------------------

UBE2O is also implicated in endosomal protein trafficking, an essential cellular process that is deregulated in several diseases and targeted by pathogens, through its ubiquitination of the WASH regulatory complex ([@b28-molce-41-3-168]), and likewise plays a role in BMP7-induced adipogenesis via monoubiquitination of SMAD6 ([@b98-molce-41-3-168]). UBE2O can also ubiquitinate the tumor-suppressive DUB BAP1 and regulate its subcellular localization and function in chromatin remodeling ([@b52-molce-41-3-168]). Other recent works have revealed a close association between UBE2O and interleukin-1 (IL-1) signaling: (1) UBE2O binds to TRAF6 and inhibit its K63-polyubiquitination, and thereby prevents the activation of NF-κB by IL-1 ([@b99-molce-41-3-168]) and (2) UBE2O interacts with and induces degradation of wild-type mixed lineage leukemia (MLL) but not MLL fusion chimera proteins ([@b46-molce-41-3-168])([Fig. 4](#f4-molce-41-3-168){ref-type="fig"}). Notably, IRAK4, which is activated by signaling from the IL-1 receptor, can phosphorylate UBE2O, leading to enhanced UBE2O-MLL interaction and subsequent degradation of MLL protein. This novel finding may pave a new way for treatment of MLL-rearranged leukemia via small-molecule inhibitors of IRAK4 or UBE2O.

E2S AS POTENTIAL DRUGGABLE TARGETS
==================================

The biological and clinical relevance of E2s to the pathogenesis and progression of diseases and cancer suggest that E2s potentially hold great therapeutic promise as druggable targets ([@b29-molce-41-3-168]; [@b61-molce-41-3-168]). In this regard, new strategies to target E2s must be more effective and selective than those for E1s because E2s play critical roles in dictating the final Ub-product and the relevant substrate's ultimate fate. The recent advances in our knowledge of the structure and functions of E2s have revealed that they are essential for Ub\~substrate specificity, and thus these conjugating enzymes have emerged as potential small-molecule therapeutic targets.

The discovery of the first small-molecule allosteric inhibitor of UBE2R1 (also known as CDC34) CC0651 underscores the feasibility of selectively inhibiting Ub transfer at the central step in the ubiquitination pathway ([@b9-molce-41-3-168]). Treatment of human cancer cells with CC0651 leads to a lower proliferation rate without significant effect on the interactions between UBE2R1, E1s, and E3s. The recently developed small-molecule inhibitor NSC697923 targets UBE2N to inhibit proliferation and survival of neuroblastoma, and also diffuses large B-cell lymphoma (DLBCL) cells ([@b13-molce-41-3-168]; [@b64-molce-41-3-168]). Despite recent progress in the development of additional small-molecule E2 inhibitors ([@b11-molce-41-3-168]; [@b54-molce-41-3-168]; [@b66-molce-41-3-168]), no such E2-targeting therapy has yet made its way to clinical trials. Interestingly, arsenic, which can crosslink adjacent cysteines within the catalytic domains of UBE2O, could serve as the basis of an alternative approach to inhibiting E2 activity, and is currently being tested against various forms of cancer in clinical trials (<https://clinicaltrials.gov>) ([@b83-molce-41-3-168]). It is also expected that E2-targeting therapeutics will be more efficacious against diseases and cancer when used in combination with current chemotherapy regimens.

CONCLUSION AND PERSPECTIVE
==========================

In the past, only the mechanisms common to all E2s, such as Ub transfer, were clearly understood; but our knowledge of E2s is now entering a second phase, in which researchers are uncovering the differences between E2s in specific physiological contexts, particularly those relevant to the pathogenesis of disease. Indeed, emerging evidence has persuasively demonstrated that deregulation of E2s can lead to debilitating disorders. Thus E2s could potentially serve as druggable targets in the treatment of disease. Although many groups across the globe, including several pharmaceutical companies, have initiated the development of new agents to target E2s, this mode of therapy has not yet made its way to clinical trials. A major obstacle to applying E2-targeting therapies in the clinic is the potential for off-target effects and side-effects due to the broad range of substrates and functions affected by E2s. Thus there is an urgent need for further research to both address the unique action modes of individual E2s in different biological contexts, and elucidate the pathogenesis of specific diseases. Ultimately, the development of novel strategies targeting individual E2s or specific interactions of E2--E3 pairs may lead to promising treatment options for cancer and other disorders in the years to come.
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![Structural representation of E2s\
Crystal structure of human UBE2D2(Protein Data Bank (PDB) code 2CLW) as a representative of the UBC fold conserved among E2s. The UBC core is comprised of four α-helices (pink colored) and an antiparallel β-sheet formed by four β-strands (yellow colored). The N- and C--termini of the domain are indicated. The location of the E3-binding site (L1 loop and L2 loop) and the active site cysteine (Cys85)(L3 loop) are also indicated.](molce-41-3-168f1){#f1-molce-41-3-168}

![Classification of E2s\
Four classes of E2s are depicted in different colored boxes upon the absence (class I) or presence of additional extensions in the N- or C--terminal of the UBC domain (class II or class III, respectively) or in both termini (class IV).](molce-41-3-168f2){#f2-molce-41-3-168}

![Scheme of UBE2O functional domains\
Shown are CR1 (conserved region 1), CR2 (conserved region 2), CR3 (conserved region 3), CC (coiled-coil domain) and UBC (ubiquitin-conjugating domain) containing an active site cysteine (Cys1040). Two putative nuclear localization signals and multiple predicted phosphorylation sites are also indicated.](molce-41-3-168f3){#f3-molce-41-3-168}

![Pathogenetic roles ofUBE2O\
*(Top) A central role of UBE2O for erythropoiesis.* UBE2O confers the erythroid differentiation through promoting the ubiquitination of free ribosomal proteins (1) and unassembled α-globin (2) and thereby remodeling the differentiation-linked proteome. *(Bottom) An oncogenic role of UBE2O in cancer*. UBE2O ubiquitinates and promotes ubiquitination and degradation of wild-type MLL but not MLL fusion proteins in MLL leukemia (1). Furthermore, UBE2O promotes mTOR− and HIF1α--mediated tumorigenesis through selectively targeting the AMPKα2 protein (2).](molce-41-3-168f4){#f4-molce-41-3-168}

###### 

Pathological roles of E2s in human diseases

  Name            Synonyms                           Biological roles                                                                                                                                                                                                                                                                                                        Relevant diseases
  --------------- ---------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------
  UBE2A           UBC2, HR6A, HHR6A, RAD6A           DNA repair ([@b40-molce-41-3-168]); Transcription regulation                                                                                                                                                                                                                                                            Cancer ([@b76-molce-41-3-168]); Cognitive disability ([@b6-molce-41-3-168]); Skeletal muscle atrophy ([@b60-molce-41-3-168])
  UBE2B           UBC2, HR6B, HHR6B, RAD6B, E2-17K   DNA repair ([@b89-molce-41-3-168]); Spermatogenesis ([@b68-molce-41-3-168])                                                                                                                                                                                                                                             Idiopathic azoospermia ([@b55-molce-41-3-168]); Skeletal muscle atrophy ([@b60-molce-41-3-168])
  UBE2C           UBCH10, DJ447F3.2, EC 6.3.2.19     Cell cycle progression ([@b80-molce-41-3-168])                                                                                                                                                                                                                                                                          Cancer ([@b81-molce-41-3-168]; [@b63-molce-41-3-168])
  UBE2D1          SFT, UBCH5, UBC4/5, UBCH5A         DNA repair ([@b70-molce-41-3-168]); Iron transport ([@b22-molce-41-3-168])                                                                                                                                                                                                                                              Cancer ([@b75-molce-41-3-168]); Hemochromatosis ([@b22-molce-41-3-168])
  UBE2D2          UBCH5B, UBC4                       DNA repair ([@b70-molce-41-3-168]); Parkin-mediated mitophagy ([@b23-molce-41-3-168])                                                                                                                                                                                                                                   Parkinson disease ([@b19-molce-41-3-168]; [@b23-molce-41-3-168])
  UBE2D3          UBC4/5, UBCH5C                     DNA repair ([@b70-molce-41-3-168]); NF-κB signaling ([@b74-molce-41-3-168])                                                                                                                                                                                                                                             Parkinson disease ([@b19-molce-41-3-168]; [@b23-molce-41-3-168]); Infectious disease ([@b62-molce-41-3-168])
  UBE2D4          HBUCE1, UBCH5D                     DNA repair ([@b70-molce-41-3-168])                                                                                                                                                                                                                                                                                      Cancer ([@b67-molce-41-3-168])
  UBE2E1          UBCH6                              PTEN ubiquitination and transport ([@b12-molce-41-3-168])                                                                                                                                                                                                                                                               Cancer ([@b50-molce-41-3-168]); Sjogren's syndrome ([@b17-molce-41-3-168])
  UBE2E2 UBE2E3   UBCH8, FLJ25157 UBCH9, UBCM2       Glucose homeostasis ([@b90-molce-41-3-168]) NRF2 transport ([@b58-molce-41-3-168]); Epithelial Na^+^ transport ([@b15-molce-41-3-168])                                                                                                                                                                                  Diabetes ([@b91-molce-41-3-168]; [@b90-molce-41-3-168]) Liddle's syndrome ([@b15-molce-41-3-168])
  UBE2F           NCE2                               Protein neddylation ([@b101-molce-41-3-168])                                                                                                                                                                                                                                                                            Cancer ([@b101-molce-41-3-168])
  UBE2G1          UBE2G                              Skeletal muscle protein regulation ([@b86-molce-41-3-168])                                                                                                                                                                                                                                                              Skeletal muscle atrophy ([@b60-molce-41-3-168])
  UBE2G2          UBC7                               ER-associated degradation (ERAD) ([@b47-molce-41-3-168])                                                                                                                                                                                                                                                                Cancer ([@b53-molce-41-3-168]); Sjogren's syndrome ([@b3-molce-41-3-168])
  UBE2H           UBC8, UBCH, UBCH2, E2-20K          Histone and cytoskeleton ubiquitination ([@b35-molce-41-3-168])                                                                                                                                                                                                                                                         Autism ([@b85-molce-41-3-168])
  UBE2I           UBC9, UBCH9                        SUMO E2 ([@b95-molce-41-3-168])                                                                                                                                                                                                                                                                                         Cancer ([@b95-molce-41-3-168])
  UBE2J1          UBC6p, CGI-76, NCUBE1, HSPC153     ERAD ([@b8-molce-41-3-168]); Spermiogenesis ([@b39-molce-41-3-168])                                                                                                                                                                                                                                                     Sjogren's syndrome ([@b3-molce-41-3-168]); Skeletal muscle atrophy ([@b60-molce-41-3-168])
  UBE2J2          NCUBE2, PRO2121                    ERAD ([@b44-molce-41-3-168])                                                                                                                                                                                                                                                                                            Cancer ([@b44-molce-41-3-168])
  UBE2K           HIP2, LIG, UBC1, E2-25K            Aggregate formation of expanded polyglutamine proteins ([@b14-molce-41-3-168])                                                                                                                                                                                                                                          Huntington Disease ([@b14-molce-41-3-168])
  UBE2L3          E2-F1, UBCH7, UBCM4                NF-κB signaling ([@b33-molce-41-3-168])                                                                                                                                                                                                                                                                                 Lupus erythematosus and rheumatoid arthritis ([@b27-molce-41-3-168]; [@b77-molce-41-3-168])
  UBE2L6          RIG-B, UBCH8, MGC8489              Autophagy ([@b18-molce-41-3-168])                                                                                                                                                                                                                                                                                       Cancer ([@b18-molce-41-3-168])
  UBE2M           UBC12, UBC-RS2                     Protein neddylation ([@b72-molce-41-3-168])                                                                                                                                                                                                                                                                             Hypertension ([@b71-molce-41-3-168])
  UBE2N           UBCH-BEN, UBC13, MGC8489           DNA repair ([@b1-molce-41-3-168])                                                                                                                                                                                                                                                                                       Parkinson disease ([@b19-molce-41-3-168])
  UBE2NL          Li174                              Cell cycle progression ([@b66-molce-41-3-168])                                                                                                                                                                                                                                                                          Cancer ([@b66-molce-41-3-168])
  UBE2O           E2-230K, FLJ12878, KIAA1734        AMPKα2 ubquitination and degradation ([@b83-molce-41-3-168]); MLL ubiquitination and degradation ([@b46-molce-41-3-168]); Erythroid differentiation and proteostasis ([@b56-molce-41-3-168]; [@b92-molce-41-3-168]); Adipocyte differentiation ([@b98-molce-41-3-168]); Endocytic trafficking ([@b28-molce-41-3-168])   Cancer([@b52-molce-41-3-168]; [@b46-molce-41-3-168]; [@b83-molce-41-3-168]); Microcytic anemia ([@b56-molce-41-3-168])
  UBE2Q1          GTAP, UBE2Q, NICE-5, PRO3094       β-catenin-EGFR-PI3K-AKT-mTOR signaling ([@b100-molce-41-3-168])                                                                                                                                                                                                                                                         Cancer ([@b100-molce-41-3-168])
  UBE2Q2                                             Apoptosis ([@b2-molce-41-3-168])                                                                                                                                                                                                                                                                                        Cancer ([@b2-molce-41-3-168]); Chronic kidney disease ([@b43-molce-41-3-168])
  UBE2QL          FLJ25076, LOC134111                Unknown                                                                                                                                                                                                                                                                                                                 Unknown
  UBE2R1          CDC34, UBCH3, UBC3, E2-CDC34       Cell cycle progression ([@b9-molce-41-3-168])                                                                                                                                                                                                                                                                           Cancer ([@b9-molce-41-3-168]); Parkinson disease ([@b19-molce-41-3-168])
  UBE2R2          UBC3B, CDC34B                      β-catenin degradation ([@b73-molce-41-3-168])                                                                                                                                                                                                                                                                           Unknown
  UBE2S           E2-EPF                             Cell cycle progression ([@b20-molce-41-3-168])                                                                                                                                                                                                                                                                          Cancer ([@b20-molce-41-3-168]); Parkinson disease ([@b23-molce-41-3-168])
  UBE2T           PIG50, HSPC150, FANCT              DNA repair ([@b51-molce-41-3-168])                                                                                                                                                                                                                                                                                      Cancer ([@b96-molce-41-3-168]); Fanconi anemia ([@b31-molce-41-3-168])
  UBE2U           MGC35130, RP4-636O23.1             DNA repair ([@b25-molce-41-3-168])                                                                                                                                                                                                                                                                                      Riddle's syndrome ([@b25-molce-41-3-168])
  UBE2W           FLJ11011, UBC-16, UBC16            E2 for α-amino group ubiquitination ([@b84-molce-41-3-168])                                                                                                                                                                                                                                                             Fanconi anemia ([@b97-molce-41-3-168])
  UBE2Z           HOYS7, FLJ13855, USE1              FAT10 conjugation ([@b69-molce-41-3-168])                                                                                                                                                                                                                                                                               Coronary artery disease ([@b49-molce-41-3-168])
  BIRC6           BRUCE, APOLLON, FLJ13726           Anti-apoptosis ([@b4-molce-41-3-168]); DNA repair ([@b21-molce-41-3-168])                                                                                                                                                                                                                                               Cancer ([@b4-molce-41-3-168])

[^1]: These authors contributed equally to this work.
